A Randomized, Open-label, Parallel, Phase 2a Study to Determine the Tolerability, Pharmacokinetics, and Efficacy of APD371 in Subjects With Crohn's Disease Experiencing Abdominal Pain

Trial Profile

A Randomized, Open-label, Parallel, Phase 2a Study to Determine the Tolerability, Pharmacokinetics, and Efficacy of APD371 in Subjects With Crohn's Disease Experiencing Abdominal Pain

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs APD 371 (Primary)
  • Indications Abdominal pain
  • Focus Adverse reactions
  • Sponsors Arena Pharmaceuticals
  • Most Recent Events

    • 07 Aug 2017 According to an Arena Pharmaceuticals media release, data readout from the study is expected around year-end 2017 to Q1 2018.
    • 15 May 2017 Status changed from planning to recruiting.
    • 14 Mar 2017 According to an Arena Pharmaceuticals media release, the company is currently incorporating feedback related to study design and conduct into the clinical protocol design and selecting sites.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top